ProPhase Labs (NASDAQ:PRPH) Announces Earnings Results, Misses Expectations By $0.05 EPS

ProPhase Labs (NASDAQ:PRPH) announced its earnings results on Wednesday. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05), FiscalAI reports. The business had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $5.69 million.

ProPhase Labs Trading Down 9.5%

Shares of NASDAQ PRPH traded down $0.02 during trading on Wednesday, hitting $0.23. 1,516,876 shares of the company traded hands, compared to its average volume of 5,463,713. The firm has a market capitalization of $9.70 million, a P/E ratio of -0.40 and a beta of -0.28. The company has a quick ratio of 0.93, a current ratio of 0.96 and a debt-to-equity ratio of 0.20. The company has a 50-day moving average price of $0.42 and a 200-day moving average price of $0.38. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $0.93.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PRPH. Wall Street Zen upgraded shares of ProPhase Labs to a “hold” rating in a report on Saturday, September 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ProPhase Labs in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On ProPhase Labs

A hedge fund recently raised its stake in ProPhase Labs stock. Susquehanna International Group LLP raised its position in ProPhase Labs, Inc. (NASDAQ:PRPH) by 290.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 397,914 shares of the company’s stock after purchasing an additional 295,899 shares during the quarter. Susquehanna International Group LLP owned 0.96% of ProPhase Labs worth $182,000 at the end of the most recent quarter. Institutional investors own 9.45% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.